Glafabra Therapeutics — The re-administrable, non-myeloablative cell-based gene therapy for lysosomal storage disorders.

FDA Orphan Drug Designation granted for GT-GLA-S03 | Pilot clinical trial complete (Canada) | U.S. IND target Q1 2027

Live-cel is an investigational treatment. It is not approved by the FDA or Health Canada and is currently being studied in a clinical trial. Patients should speak with their Fabry specialist before making any treatment decisions.